Skip to main navigation Skip to search Skip to main content

Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International Immunocancer Registry (ICIR)

  • ICIR
  • IDIBAPSCELLEX
  • University of Barcelona
  • CHU Montpellier
  • University of Texas MD Anderson Cancer Center
  • Assistance publique – Hôpitaux de Paris
  • Commissariat à l’énergie atomique et aux énergies alternatives
  • Birmingham Biomedical Research Centre
  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
  • ICMiD
  • University of Pisa
  • Johns Hopkins University
  • Hospital CIMA-Sanitas
  • Université de Strasbourg
  • T.T.)
  • Utrecht University
  • Ludwig Maximilian University of Munich
  • Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
  • King's College London
  • Institut national de la santé et de la recherche médicale
  • August Pi i Sunyer Biomedical Research Institute
  • Argentinian Registry
  • GEAS-SEMI Spanish Registry
  • Mayo Clinic Rochester, MN
  • Sheba Medical Center at Tel Hashomer
  • Tel Aviv University
  • Unité INSERM U753, Institut de Cancérologie Gustave Roussy
  • University of Melbourne
  • Diakonhjemmet Hospital
  • Christian Medical College
  • Lund University
  • Kanazawa University
  • Hacettepe University
  • Instituto Nacional de Cancerologia
  • Universidade Federal de São Paulo
  • University of Ljubljana
  • University of Debrecen
  • Hyogo Medical University

Research output: Contribution to journal › Article › peer-review

104 Scopus citations

Abstract

Objective. To analyse the worldwide occurrence of sicca/Sjögren's (SS) syndrome associated with the use of immune checkpoint inhibitors (ICI) in patients with cancer. Methods. The ImmunoCancer International Registry (ICIR) is a Big Data- Sharing multidisciplinary network composed by 40 specialists in Rheumatology, Internal Medicine, Immunology and Oncology from 18 countries focused on the clinical and basic research of the immune-related adverse events (irAEs) related to cancer immunotherapies. For this study, patients who were investigated for a clinical suspicion of SS after being exposed to ICI were included. Results. We identified 26 patients (11 women and 15 men, with a mean age at diagnosis of 63.57 years). Underlying cancer included lung (n=12), renal (n=7), melanoma (n=4), and other (n=3) neoplasia. Cancer immunotherapies consisted of monotherapy (77%) and combined regimens (23%). In those patients receiving monotherapy, all patients were treated with PD-1/PD-L1 inhibitors (nivolumab in 9, pembrolizumab in 7 and durvalumab in 4); no cases associated with CTLA-4 inhibitors were identified. The main SS-related features consisted of dry mouth in 25 (96%) patients, dry eye in 17 (65%), abnormal ocular tests in 10/16 (62%) and abnormal oral diagnostic tests in 12/14 (86%) patients. Minor salivary gland biopsy was carried out in 15 patients: histopathological findings consisted of mild chronic sialadenitis in 8 (53%) patients and focal lymphocytic sialadenitis in the remaining 7 (47%); a focus score was measured in 5 of the 6 patients (mean of 1.8, range 1-4). Immunological markers included positive ANA in 13/25 (52%), anti-Ro/ SS-A in 5/25 (20%), RF in 2/22 (9%), anti-La/SS-B in 2/25 (8%), low C3/C4 levels in 1/17 (6%) and positive cryoglobulins in 1/10 (10%). Classification criteria for SS were fulfilled by 10 (62%) out of 16 patients in whom the two key classificatory features were carried out. Among the 26 patients, there were only 3 (11%) who presented exclusively with sicca syndrome without organ-specific autoimmune manifestations. Therapeutic management included measures directed to treat sicca symptoms and therapies against autoimmune-mediated manifestations (glucocorticoids in 42%, second/ third-line therapies in 31%); therapeutic response for systemic features was observed in 8/11 (73%). No patient died due to autoimmune involvement. Conclusion. Patients with Sjögren's syndrome triggered by ICI display a very specific profile different from that reported in idiopathic primary SS, including more frequent occurrence in men, a higher mean age, a predominant immunonegative serological profile, and a notable development of organ-specific autoimmune involvement in spite of the poor immunological profile. The close association found between sicca/Sjögren's syndrome and primarily PD-1 blockade requires further specific investigation.

Original languageEnglish
Pages (from-to)S114-S122
JournalClinical and Experimental Rheumatology
Volume37
StatePublished - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Durvalumab
  • Immune checkpoint inhibitors
  • Nivolumab
  • Pembrolizumab
  • Sjögren's syndrome

Fingerprint

Dive into the research topics of 'Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International Immunocancer Registry (ICIR)'. Together they form a unique fingerprint.

Cite this